Search

Your search keyword '"Bogni, A."' showing total 23 results
Start Over Author "Bogni, A." Publisher sage publications
23 results on '"Bogni, A."'

2. Metabolism and Neurotoxicity: The Significance of Genetically Engineered Cell Lines and New Three-Dimensional Cell Cultures

Author

Joanne Gartion, Alessia Bogni, Erwin van Vliet, Ingrid Langezaal, Agnieszka Kinsner, Sandra Coecke, Nicholaos Parissis, Chantra Eskes, and Laura Raimondo

Subjects
Chemical compound, Computational biology, Biology, Animal Testing Alternatives, Toxicology, Nervous System, PC12 Cells, General Biochemistry, Genetics and Molecular Biology, Xenobiotics, chemistry.chemical_compound, Cricetulus, In vivo, Cricetinae, medicine, Animals, Humans, media_common.cataloged_instance, European Union, European union, media_common, Neurotoxicity, Reproducibility of Results, General Medicine, Metabolism, medicine.disease, In vitro, Rats, Organoids, Medical Laboratory Technology, chemistry, Cell culture, Toxicity, Nervous System Diseases, Genetic Engineering
Abstract

Until now, no in vitro methods for determining neurotoxic effects, on Phase I and Phase II biotransformation-driven metabolite formation or for the evaluation of the metabolism-mediated hazard of a chemical, have been validated. The current test guidelines are based on studies in vivo, involving animals exposed to the test substance. Novel in vitro testing instead of animal testing is required by Directive 86/609/EEC. In the EU White Paper on a Strategy for a Future Chemicals Policy, which may result in up to 20,000 chemicals being screened for toxicity, the use of non-animal test methods is seen as essential and is encouraged. The aim of the present work was to demonstrate the significance of novel technologies, including the use of genetically engineered cell lines and three-dimensional cell culture techniques for direct application in the regulatory hazard-assessment process. Furthermore, attempts were made to make in vitro toxicity tests for specific applications more-readily available for inclusion in the chemical hazard-assessment process, by exploiting advances made in the life sciences.

Published
2002
Full Text
View/download PDF

3. The Role of Serum Carcinoembryonic Antigen (CEA) in the Management of Patients with Colorectal Carcinoma: The Experience of the Istituto Tumori of Milan

Author

Anna Bogni, G.L. Buraggi, E. De Jager, Flavio Crippa, Ettore Seregni, and Emilio Bombardieri

Subjects
Adult, Male, Curative resection, Cancer Research, medicine.medical_specialty, Colorectal cancer, Clinical Biochemistry, Rectum, Gastroenterology, 030218 nuclear medicine & medical imaging, Pathology and Forensic Medicine, 03 medical and health sciences, 0302 clinical medicine, Carcinoembryonic antigen, Internal medicine, medicine, Carcinoma, Humans, Neoplasm Metastasis, Stage (cooking), Aged, Retrospective Studies, Aged, 80 and over, Epithelioma, biology, business.industry, Retrospective cohort study, Middle Aged, Prognosis, medicine.disease, Carcinoembryonic Antigen, Surgery, medicine.anatomical_structure, Italy, Oncology, 030220 oncology & carcinogenesis, biology.protein, Female, Neoplasm Recurrence, Local, Colorectal Neoplasms, business
Abstract

CEA determination has attained an important role in the clinical management of patients with tumors of the colorectal tract. In this paper the experience of the Istituto Tumori of Milan is reviewed and the results are discussed. Three hundred and thirty-six patients were followed after curative resection of colorectal carcinoma. The follow-up period was 15 years, from January 1975 to December 1990 (global follow-up 1358 years). In the course of follow-up 136 patients developed recurrent disease. The number of CEA determinations for each patient ranged from 1 to 37 (mean 8, total 3330). CEA levels of presurgical patients were related to the clinical stage. Among patients who developed recurrences 61% showed an increase in CEA serum levels. In 200 patients with a negative follow-up we observed only 15 cases of false-positive results.

Published
1992
Full Text
View/download PDF

4. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology

Author

M. Bianchi, Marzio Gabrielli, M. Fontanesi, Anna Bogni, P. Veronesi, Gabriella Becchi, E. Bombardieri, A. Tardini, and G. Saccani Jotti

Subjects
0301 basic medicine, Cancer Research, Receptor Status, 030102 biochemistry & molecular biology, Oncogene, medicine.diagnostic_test, Clinical Biochemistry, Biology, Cell cycle, medicine.disease, Pathology and Forensic Medicine, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Oncology, 030220 oncology & carcinogenesis, Ki-67, Biopsy, Cancer research, medicine, biology.protein, Immunohistochemistry, Grading (tumors)
Abstract

The expression of oncogene products related to cell growth (c-erbB-2, c-myc, ras p21, EGFR) was investigated in benign (15 cases) and malignant breast lesions (20 cases) by means of immunohistochemistry using the avidin-biotin-peroxidase technique with polyclonal and monoclonal antibodies. The aim of this study was to evaluate the relationship between the staining positivity and various morphological and biological features, such as tumour type, grading, hormone receptor status and cell kinetic parameters. In benign breast lesions, as expected, the kinetic parameters were low, both for Ki-67 and LI. All the specimens showed a diploid condition (the DI being equal to 1) and we found a limited degree of immunoreactivity for all the growth factors and oncogene products. In breast cancer we studied the distribution of immunohistochemical positivity for EGFR, c-erbB-2, c-myc, ras p21 and Ki-67, which was related to age, nodal status, ER and PgR receptor status, LI, DI and histopathological grading. A significant positive correlation was found both between ras p21 espression and nodal status and ERICA positivity. We observed a strong correlation between LI and Ki-67 and an inverse relation between Ki-67 and ER expression. These findings suggest the importance of studying the relationship between prognostic factors which may provide preoperative prediction in the biological behaviour of breast cancer, not only on biopsy specimens, but also on fine needle aspirates.

Published
1992
Full Text
View/download PDF

5. The Contribution of Positron Emission Tomography (Pet) with 18F-Fluorodeoxyglucose (Fdg) in the Preoperative Detection of Axillary Metastases of Breast Cancer: The Experience of the National Cancer Institute of Milan

Author

Flavio Crippa, Claudio Pascali, Roberto Agresti, Carlo Chiesa, Emilio Bombardieri, Mauro Schiavini, Vinicio De Sanctis, D. Decise, Vincenzo Delle Donne, and Anna Bogni

Subjects
Fluorine Radioisotopes, Cancer Research, medicine.medical_specialty, Breast Neoplasms, Deoxyglucose, Sensitivity and Specificity, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Fluorodeoxyglucose F18, medicine, Humans, Fluorodeoxyglucose, medicine.diagnostic_test, business.industry, Cancer, General Medicine, medicine.disease, Italy, Oncology, Positron emission tomography, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Axilla, Female, Lymph Nodes, Radiology, Radiopharmaceuticals, business, Nuclear medicine, Tomography, Emission-Computed, medicine.drug
Published
1997
Full Text
View/download PDF

7. Mucin Gene Expression in Lung Cancer Tissues

Author

Anna Bogni, L. Sfreddo, C. Lombardo, A. Cantoni, Emilio Bombardieri, Ettore Seregni, I. Cataldo, and C. Botti

Subjects
0301 basic medicine, Cancer Research, Lung Neoplasms, Molecular Sequence Data, Clinical Biochemistry, Gene Expression, Biology, Pathology and Forensic Medicine, 03 medical and health sciences, 0302 clinical medicine, Gene expression, Biomarkers, Tumor, medicine, Humans, Lung cancer, Mucin-2, Membrane Glycoproteins, Base Sequence, Mucin-1, Mucin, Mucins, medicine.disease, Neoplasm Proteins, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research
Published
1994
Full Text
View/download PDF

8. CA 15.3 as a signal of undetectable breast cancer metastases in a follow-up period of 4 years

Author

E. De Jager, Maria Antonietta Pizzichetta, Lorenzo Maffioli, Emilio Bombardieri, Anna Bogni, Aurora Costa, and Ettore Seregni

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Medical screening, Period (gene), Clinical Biochemistry, CA 15-3, medicine.disease, Tumor associated antigen, Pathology and Forensic Medicine, Surgery, Metastasis, Breast cancer, Internal medicine, medicine, business
Published
1992
Full Text
View/download PDF

9. The Influence of Blood Glucose Levels on [18F]Fluorodeoxyglucose (Fdg) Uptake in Cancer: A Pet Study in Liver Metastases from Colorectal Carcinomas

Author

Crippa, Flavio, primary, Gavazzi, Cecilia, additional, Bozzetti, Federico, additional, Chiesa, Carlo, additional, Pascali, Claudio, additional, Bogni, Anna, additional, De Sanctis, Vinicio, additional, Decise, Donatella, additional, Schiavini, Mauro, additional, Cucchetti, Gianenrico, additional, and Bombardieri, Emilio, additional

Published
1997
Full Text
View/download PDF

11. Radiopharmaceuticals for Breast Cancer Imaging

Author

Maffioli, Lorenzo, primary, Seregni, Ettore, additional, Chiti, Arturo, additional, Molteni, Silvia Nerini, additional, Crippa, Flavio, additional, Botti, Carlo, additional, Bogni, Anna, additional, Agresti, Roberto, additional, and Bombardieri, Emilio, additional

Published
1997
Full Text
View/download PDF

12. The Contribution of Positron Emission Tomography (Pet) with 18F-Fluorodeoxyglucose (Fdg) in the Preoperative Detection of Axillary Metastases of Breast Cancer: The Experience of the National Cancer Institute of Milan

Author

Crippa, Flavio, primary, Agresti, Roberto, additional, Donne, Vincenzo Delle, additional, Pascali, Claudio, additional, Bogni, Anna, additional, Chiesa, Carlo, additional, De Sanctis, Vinicio, additional, Schiavini, Mauro, additional, Decise, Donatella, additional, and Bombardieri, Emilio, additional

Published
1997
Full Text
View/download PDF

15. Evaluation of Cytokeratin 19 Serum Fragments (Cyfra 21–1) in Patients with Lung Cancer: Results of a Multicenter Trial

Author

Bombardieri, E., primary, Seregni, E., additional, Bogni, A., additional, Ardit, S., additional, Belloli, S., additional, Busetto, A., additional, Caniello, B., additional, Castelli, M., additional, Cianetti, A., additional, Correale, M., additional, De Angelis, G., additional, Gandolfo, G.M., additional, Gion, M., additional, Macchia, V., additional, Mione, R., additional, Navaglia, F., additional, Onetto, M., additional, Paganuzzi, M., additional, Pecchio, F., additional, Plebani, M., additional, Rapellino, M., additional, Ruggeri, G., additional, Vannini, P., additional, Vitelli, G., additional, and Zamperlin, A., additional

Published
1994
Full Text
View/download PDF

23. Metabolism-mediated neurotoxicity: the significance of genetically engineered cell lines and new three-dimensional cell cultures.

Author

Coecke S, Eskes C, Gartion J, Vliet EV, Kinsner A, Bogni A, Raimondo L, Parissis N, and Langezaal I

Subjects
Animals, Cricetinae, Cricetulus, European Union, Humans, PC12 Cells, Rats, Reproducibility of Results, Xenobiotics classification, Animal Testing Alternatives, Genetic Engineering, Nervous System drug effects, Nervous System metabolism, Nervous System Diseases chemically induced, Nervous System Diseases metabolism, Nervous System Diseases pathology, Organoids drug effects, Organoids metabolism, Organoids pathology, Xenobiotics metabolism, Xenobiotics toxicity
Abstract

Until now, no in vitro methods for determining neurotoxic effects, on Phase I and Phase II biotransformation-driven metabolite formation or for the evaluation of the metabolism-mediated hazard of a chemical, have been validated. The current test guidelines are based on studies in vivo, involving animals exposed to the test substance. Novel in vitro testing instead of animal testing is required by Directive 86/609/EEC. In the EU White Paper on a Strategy for a Future Chemicals Policy, which may result in up to 20,000 chemicals being screened for toxicity, the use of non-animal test methods is seen as essential and is encouraged. The aim of the present work was to demonstrate the significance of novel technologies, including the use of genetically engineered cell lines and three-dimensional cell culture techniques for direct application in the regulatory hazard-assessment process. Furthermore, attempts were made to make in vitro toxicity tests for specific applications more-readily available for inclusion in the chemical hazard-assessment process, by exploiting advances made in the life sciences.

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results